- Home
- About
- PsychU For You
- Topics
- Mental Health Disorders
- Agitation
- Bipolar Disorder
- Depression
- Pseudobulbar Affect (PBA)
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Health Care Policy, Quality & Payer Administration
- Long-Term Care
- Stigma
- Suicide Awareness
- Wellness
- Events
- Content
- Supporting Organizations
Virtual Event – Strategies To Optimize Patient Outcomes In Bipolar I Disorder: The Role Of Long-Acting Injectable Antipsychotics

Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Virtual Event – Strategies To Optimize Patient Outcomes In Bipolar I Disorder: The Role Of Long-Acting Injectable Antipsychotics
This is a Virtual Event for PsychU members in Pennsylvania, Delaware, New Jersey, West Virginia, and Maryland.
In this presentation, the objectives are to:
- Understand the impact of mood episode recurrence in bipolar I disorder on patient functioning and clinical outcomes
- Discuss risk factors for mood episode recurrence, including nonadherence, in patients with bipolar I disorder
- Review management strategies, including long-acting injectable antipsychotics (LAIs), to optimize patient outcomes in bipolar I disorder

Mark Tacelosky, PharmD
Senior Medical Science Liaison

Katie Sulkowski, PharmD
Medical Science Liaison
Speakers Mark Tacelosky, PharmD and Katie Sulkowski, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC)